RNA knockdown as a potential therapeutic strategy in Parkinson's disease

Gene Therapy

Volumn 13, Issue 6, 2006, Pages 517-524

  Manfredsson, F P ^a   Lewin, A S ^a   Mandel, R J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; IMMUNOLIPOSOME; LEVODOPA; MACROGOL; MITOCHONDRIAL PROTEIN; PARKIN; POLYETHYLENEIMINE; PROTEIN DJ 1; PROTEIN PINK 1; SMALL INTERFERING RNA; UBIQUITIN THIOLESTERASE; UNCLASSIFIED DRUG;

DEGENERATIVE DISEASE; DISEASE COURSE; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; DYSKINESIA; ELDERLY CARE; FAMILIAL DISEASE; GENE OVEREXPRESSION; HUMAN; NERVE CELL DEGENERATION; NEUROLOGIC DISEASE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PARKINSON DISEASE; PREVALENCE; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; RNA INTERFERENCE; SUBSTANTIA NIGRA; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS VECTOR;

ANIMALS; CELL DEATH; GENE EXPRESSION REGULATION; GENE THERAPY; HUMANS; PARKINSON DISEASE; PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

ANIMALIA;

EID: 33645159024     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302669     Document Type: Review

References (68)

1. Ketting RF, Haverkamp TH, van Luenen HG, Plasterk RH. Mut-7 of C. elegans, required for transposon silencing and RNA interference, is a homolog of Werner syndrome helicase and RNaseD. Cell 1999; 99: 133-141.
2. Meister G, Tuschl T. Mechanisms of gene silencing by double-stranded RNA. Nature 2004; 431: 343-349.
3. Filipowicz W, Jaskiewicz L, Kolb FA, Pillai RS. Post-transcriptional gene silencing by siRNAs and miRNAs. Curr Opin Struct Biol 2005; 15: 331-341.
4. Tomari Y, Zamore PD. Perspective: Machines for RNAi. Genes Dev 2005; 19: 517-529.
5. Jin P, Alisch RS, Warren ST. RNA and microRNAs in fragile X mental retardation. Nat Cell Biol 2004; 6: 1048-1053.
6. Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, Khvorova A. Rational siRNA design for RNA interference. Nat Biotechnol 2004; 22: 326-330.
7. Schwarz DS, Hutvagner G, Du T, Xu Z, Aronin N, Zamore PD. Asymmetry in the assembly of the RNAi enzyme complex. Cell 2003; 115: 199-208.
8. Khvorova A, Reynolds A, Jayasena SD. Functional siRNAs and miRNAs exhibit strand bias. Cell 2003; 115: 209-216.
9. Dorsett Y, Tuschl T. siRNAs: Applications in functional genomics and potential as therapeutics. Nat Rev Drug Discov 2004; 3: 318-329.
10. Akashi H, Matsumoto S, Taira K. Gene discovery by ribozyme and siRNA libraries. Nat Rev Mol Cell Biol 2005; 6: 413-422.
11. Luo B, Heard AD, Lodish HF. Small interfering RNA production by enzymatic engineering of DNA (SPEED). Proc Natl Acad Sci USA 2004; 101: 5494-5499.
12. Sen G, Wehrman TS, Myers JW, Blau HM. Restriction enzyme-generated siRNA (REGS) vectors and libraries. Nat Genet 2004; 36: 183-189.
13. Seyhan AA, Vlassov AV, Ilves H, Egry L, Kaspar RL, Kazakov SA et al. Complete, gene-specific siRNA libraries: Production and expression in mammalian cells. RNA 2005; 11: 837-846.
14. Czauderna F, Fechtner M, Dames S, Aygun H, Klippel A, Pronk GJ et al. Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res 2003; 31: 2705-2716.
15. Hamada M, Ohtsuka T, Kawaida R, Koizumi M, Morita K, Furukawa H et al. Effects on RNA interference in gene expression (RNAi) in cultured mammalian cells of mismatches and the introduction of chemical modifications at the 3′-ends of siRNAs. Antisense Nucleic Acid Drug Dev 2002; 12: 301-309.
16. Prakash TP, Allerson CR, Dande P, Vickers TA, Sioufi N, Jarres R et al. Positional effect of chemical modifications on short interference RNA activity in mammalian cells. J Med Chem 2005; 48: 4247-4253.
17. Zhou H, Xia XG, Xu Z. An RNA polymerase II construct synthesizes short-hairpin RNA with a quantitative indicator and mediates highly efficient RNAi. Nucleic Acids Res 2005; 33: E62.
18. Boden D, Pusch O, Silbermann R, Lee F, Tucker L, Ramratnam B. Enhanced gene silencing of HIV-1 specific siRNA using micro-RNA designed hairpins. Nucleic Acids Res 2004; 32: 1154-1158.
19. Pardridge WM. Intravenous, non-viral RNAi gene therapy of brain cancer. Expert Opin Biol Ther 2004; 4: 1103-1113.
20. Akaneya Y, Jiang B, Tsumoto T. RNAi-induced gene silencing by local electroporation in targeting brain region. J Neurophysiol 2005; 93: 594-602.
21. Harper SQ, Staber PD, He X, Eliason SL, Martins IH, Mao Q et al. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci USA 2005; 102: 5820-5825.
22. Rodriguez-Lebron E, Denovan-Wright EM, Nash K, Lewin AS, Mandel RJ. Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. Mol Ther 2005; 12: 618-633.
23. Xia H, Mao Q, Eliason SL, Harper SQ, Martins IH, Orr HT et al. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med 2004; 10: 816-820.
24. Bjorklund A, Kirik D, Rosenblad C, Georgievska B, Lundberg C, Mandel RJ. Towards a neuroprotective gene therapy for Parkinson's disease: Use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. Brain Res 2000; 886: 82-98.
25. Mandel RJ, Burger C. Clinical trials in neurological disorders using AAV vectors: Promises and challenges. Curr Opin Mol Ther 2004; 6: 482-490.
26. Blacklow NR, Hoggan MD, Sereno MS, Brandt CD, Kim HW, Parrott RH et al. A seroepidemiologic study of adenovirus-associated virus infection in infants and children. Am J Epidemiol 1971; 94: 359-366.
27. Erles K, Sebokova P, Schlehofer JR. Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J Med Virol 1999; 59: 406-411.
28. Peden CS, Burger C, Muzyczka N, Mandel RJ. Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain. J Virol 2004; 78: 6344-6359.
29. Burger C, Gorbatyuk OS, Velardo MJ, Peden CS, Williams P, Zolotukhin S et al. Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol Ther 2004; 10: 302-317.
30. Mandel RJ, Spratt SK, Snyder RO, Leff SE. Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson s disease in rats. Proc Natl Acad Sci USA 1997; 94: 14083-14088.
31. Klein RL, Meyer EM, Peel AL, Zolotukhin S, Meyers C, Muzyczka N et al. Neuron-specific transduction in the rat septohippocampal or nigrostriatal pathway by recombinant adeno-associated virus vectors. Exp Neurol 1998; 150: 183-194.
32. Miller VM, Xia H, Marrs GL, Gouvion CM, Lee G, Davidson BL et al. Allele-specific silencing of dominant disease genes. Proc Natl Acad Sci USA 2003; 100: 7195-7200.
33. Venkatraman P, Wetzel R, Tanaka M, Nukina N, Goldberg AL. Eukaryotic proteasomes cannot digest polyglutamine sequences and release them during degradation of polyglutamine-containing proteins. Mol Cell 2004; 14: 95-104.
34. Bruijn LI, Houseweart MK, Kato S, Anderson KL, Anderson SD, Ohama E et al. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 1998; 281: 1851-1854.
35. Kabashi E, Agar JN, Taylor DM, Minotti S, Durham HD. Focal dysfunction of the proteasome: A pathogenic factor in a mouse model of amyotrophic lateral sclerosis. J Neurochem 2004; 89: 1325-1335.
36. Xie J, Awad KS, Guo Q. RNAi knockdown of Par-4 inhibits neurosynaptic degeneration in ALS-linked mice. J Neurochem 2005; 92: 59-71.
37. Daude N, Marella M, Chabry J. Specific inhibition of pathological prion protein accumulation by small interfering RNAs. J Cell Sci 2003; 116: 2775-2779.
38. Klockgether T. Parkinson's disease: Clinical aspects. Cell Tissue Res 2004; 318: 115-120.
39. Nutt JG. Clinical pharmacology of levodopa-induced dyskinesia. Ann Neurol 2000; 47: S160-S164; discussion S164-S166.
40. Nutt JG. Motor fluctuations and dyskinesia in Parkinson's disease. Parkinsonism Relat Disord 2001; 8: 101-108.
41. Dunnett SB, Bjorklund A, Lindvall O. Cell therapy in Parkinson's disease - stop or go? Nat Rev Neurosci 2001; 2: 365-369.
42. Lozano AM, Mahant N. Deep brain stimulation surgery for Parkinson's disease: Mechanisms and consequences. Parkinsonism Relat Disord 2004; 10 (Suppl 1): S49-S57.
43. Eriksen JL, Wszolek Z, Petrucelli L. Molecular pathogenesis of Parkinson disease. Arch Neurol 2005; 62: 353-357.
44. Tanner CM, Langston JW. Do environmental toxins cause Parkinson's disease? A critical review. Neurology 1990; 40 (Suppl): 17-30; discussion 30-31.
45. Tanner CM, Ottman R, Goldman SM, Ellenberg J, Chan P, Mayeux R et al. Parkinson disease in twins: An etiologic study. JAMA 1999; 281: 341-346.
46. Greenamyre JT, Hastings TG. Biomedicine. Parkinson's - divergent causes, convergent mechanisms. Science 2004; 304: 1120-1122.
47. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276: 2045-2047.
48. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J et al. Alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003; 302: 841.
49. Cookson MR. The Biochemistry of Parkinson's Disease. Annu Rev Biochem 2004; 74: 29-52.
50. Drolet RE, Behrouz B, Lookingland KJ, Goudreau JL. Mice lacking alpha-synudein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration. Neurotoxicology 2004; 25: 761-769.
51. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998; 392: 605-608.
52. West A, Periquet M, Lincoln S, Lucking CB, Nicholl D, Bonifati V et al. Complex relationship between Parkin mutations and Parkinson disease. Am J Med Genet 2002; 114: 584-591.
53. Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 2000; 25: 302-305.
54. Staropoli JF, McDermott C, Martinat C, Schulman B, Demireva E, Abeliovich A. Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity. Neuron 2003; 37: 735-749.
55. Yang Y, Nishimura I, Imai Y, Takahashi R, Lu B. Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila. Neuron 2003; 37: 911-924.
56. Perez FA, Palmiter RD. Parkin-deficient mice are not a robust model of parkinsonism. Proc Natl Acad Sci USA 2005; 102: 2174-2179.
57. Liu DX, Greene LA. Neuronal apoptosis at the G1/S cell cycle checkpoint. Cell Tissue Res 2001; 305: 217-228.
58. Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003; 299: 256-259.
59. Taira T, Saito Y, Niki T, Iguchi-Ariga SM, Takahashi K, Ariga H. DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep 2004; 5: 213-218.
60. Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004; 304: 1158-1160.
61. Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E et al. The ubiquitin pathway in Parkinson's disease. Nature 1998; 395: 451-452.
62. Alberi L, Sgado P, Simon HH. Engrailed genes are cell-autonomously required to prevent apoptosis in mesencephalic dopaminergic neurons. Development 2004; 131: 3229-3236.
63. Bantounas I, Glover CP, Kelly S, Iseki S, Phylactou LA, Uney JB. Assessing adenoviral hammerhead rtbozyme and small hairpin RNA cassettes in neurons: Inhibition of endogenous caspase-3 activity and protection from apoptotic cell death. J Neurosci Res 2005; 79: 661-669.
64. Lingor P, Koeberle P, Kugler S, Bahr M. Down-regulation of apoptosis mediators by RNAi inhibits axotomy-induced retinal ganglion cell death in vivo. Brain 2005; 128: 550-558.
65. Ji J, Wernli M, Mielgo A, Buechner SA, Erb P. Fas-ligand gene silencing in basal cell carcinoma tissue with small interfering RNA. Gene Therapy 2005; 12: 678-684.
66. Kirik D, Rosenblad C, Burger C, Lundberg C, Johansen TE, Muzyczka N et al. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synudein in the nigrostriatal system. J Neurosci 2002; 22: 2780-2791.
67. Kirik D, Annett LE, Burger C, Muzyczka N, Mandel RJ, Bjorklund A. Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: A new primate model of Parkinson's disease. Proc Natl Acad Sci USA 2003; 100: 2884-2889.
68. Hommel JD, Sears RM, Georgescu D, Simmons DL, DiLeone RJ. Local gene knockdown in the brain using viral-mediated RNA interference. Nat Med 2003; 9: 1539-1544.